{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:44:34Z","timestamp":1781829874033,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100006738","name":"Medicinska Fakulteten, Lunds Universitet","doi-asserted-by":"publisher","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100006738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100006189","name":"Direkt\u00f6r Albert P\u00e5hlssons Stiftelse","doi-asserted-by":"publisher","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100006189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100009780","name":"Region Sk\u00e5ne","doi-asserted-by":"publisher","award":["2021"],"award-info":[{"award-number":["2021"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100009780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment of Graves\u00b4 disease (GD) with radioiodine increases the risk of developing Graves\u00b4 ophthalmopathy (GO), and the link between thyroid and orbital tissue may be the presence of TSH-receptors. Radioiodine increases the titers of TRAb and the aim was to investigate the relationship between GO and TRAb titers after treatment with radioiodine and to define the impact of risk genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>GD patients without ophthalmopathy or previous treatment with radioiodine were prospectively included at treatment with radioiodine for hyperthyroidism. A follow-up was performed 1 year later for the registration of GO development. The study was performed at a University Hospital Clinic; a referral center of all patients treated with radioiodine in the south of Sweden. The main outcome measures were the development of TRAb, anti-TPO, and anti-TG after 3 months and GO after 12 months and relationship to the genetic background (HLA, CTLA-4, and CYR61).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Three months of radioiodine TRAb titers increased in two thirds of patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0005) but not in the other third. Anti-TPO titers were associated with TRAb (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u20090.362,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001) but not anti-TG. At follow-up 1 year later (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009204) 32 patients developed GO with a proportion of 70% in the group increasing in TRAb titers and 30% in the group with unchanged or lower TRAb titers (\n                      <jats:italic>p<\/jats:italic>\n                      -value &lt;\u20090.0005). Patients with GO had higher titers of TRAb than patients without GO. CTLA-4 (rs231775 SNP) was significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.005) associated with TRAb titers above the median three months after radioiodine.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The increase in TRAb titers after treatment with radioiodine is associated with GO and a genetic variation in CTLA-4 is associated with higher titers of TRAb.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-021-02952-2","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T14:02:36Z","timestamp":1638453756000},"page":"856-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Increased risk of Graves\u00b4ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres"],"prefix":"10.1007","volume":"75","author":[{"given":"Bushra","family":"Shahida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleoniki","family":"Tsoumani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Planck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayachitra","family":"Modhukur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Asp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sundl\u00f6v","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Tennvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"\u00c5sman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Lindgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3445-9090","authenticated-orcid":false,"given":"Mikael","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"5","key":"2952_CR1","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1210\/er.2002-0030","volume":"24","author":"Y Tomer","year":"2003","unstructured":"Y. Tomer, T.F. Davies, Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr. Rev. 24(5), 694\u2013717 (2003).","journal-title":"Endocr. Rev."},{"issue":"11","key":"2952_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1089\/thy.2007.1526","volume":"17","author":"TF Davies","year":"2007","unstructured":"T.F. Davies, Really significant genes for autoimmune thyroid disease do not exist \u2013 so how can we predict disease? Thyroid 17(11), 1027\u20131029 (2007).","journal-title":"Thyroid"},{"issue":"2","key":"2952_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/cen.12222","volume":"79","author":"WM Wiersinga","year":"2013","unstructured":"W.M. Wiersinga, Smoking and thyroid. Clin. Endocrinol. 79(2), 145\u2013151 (2013).","journal-title":"Clin. Endocrinol."},{"issue":"1","key":"2952_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000443373","volume":"5","author":"M Lantz","year":"2016","unstructured":"M. Lantz, J. Calissendorff, F. Tr\u00e4isk, L. Tallstedt, T. Planck, O. T\u00f6rring, B. Hallengren, P. \u00c5sman, Adjuvant treatment of Graves\u00b4 disease with diclofenac-safety, effects on ophthalmopathy and antibody concentrations. Eur. Thyroid J. 5(1), 50\u201357 (2016).","journal-title":"Eur. Thyroid J."},{"issue":"12","key":"2952_CR5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1089\/thy.1999.9.1175","volume":"9","author":"DHC Khoo","year":"1999","unstructured":"D.H.C. Khoo, S.C. Ho, L.L. Seah, K.S. Fong, E.S. Tai, S.P. Chee, P.H.K. Eng, S.E. Aw, A.C.K. Fok, The combination of absent thyroid peroxidise antibodies and high thyroid-stimulating immunoglobulin levels in GD identifies a group at markedly increased risk of ophthalmopathy. Thyroid 9(12), 1175\u20131180 (1999).","journal-title":"Thyroid"},{"issue":"2","key":"2952_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1055\/s-0033-1363193","volume":"122","author":"M Lantz","year":"2014","unstructured":"M. Lantz, T. Planck, P. \u00c5sman, B. Hallengren, Increased TRAb and\/or low anti-TPO titers at diagnosis of Graves\u00b4 disease (GD) are associated with an increased risk of developing ophthalmopathy after onset of GD. Exp. Clin. Endocrinol. Diabetes 122(2), 113\u2013118 (2014).","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"issue":"10","key":"2952_CR7","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1210\/jc.2009-0747","volume":"94","author":"F Tr\u00e4isk","year":"2009","unstructured":"F. Tr\u00e4isk, M. Abraham-Nordling, G. Berg, J. Calissendorff, B. Hallengren, P. Hedner, M. Lantz, E. Nystr\u00f6m, L. Tallstedt, A. Taube, O. T\u00f6rring, G. Wallin, P. \u00c5sman, G. Lundell, Thyroid associated ophthalmopathy ocurrence after treatment for Graves\u00b4 hyperthyroidism with iodine-131 or anti-thyroid drugs. J. Clin. Endocrinol. Metab. 94(10), 3700\u20133707 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2952_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/EJE-07-0450","volume":"158","author":"P Laurberg","year":"2008","unstructured":"P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, O. T\u00f6rring, TSH-receptor autoimmunity in Graves\u00b4s disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5 year prospective randomized study. Eur. J. Endocrinol. 158(1), 69\u201375 (2008).","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"2952_CR9","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/j.1365-2265.1982.tb03170.x","volume":"16","author":"S Atkinson","year":"1982","unstructured":"S. Atkinson, A.M. McGregor, P. Kendall-Taylor, M.M. Peterson, B.R. Smith, Effect of radioiodine on stimulatory activity of Graves\u2019 immunoglobulins. Clin. Endocrinol. 16(6), 537\u2013543 (1982).","journal-title":"Clin. Endocrinol."},{"issue":"6","key":"2952_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1210\/jcem-50-6-1005","volume":"50","author":"CS Teng","year":"1980","unstructured":"C.S. Teng, R.T. Yeung, R.K. Khoo, T.T. Alagaratnam, A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves\u2019 disease treated by subtotal thyroidectomy or radioactive iodine. J. Clin. Endocrinol. Metab. 50(6), 1005\u20131010 (1980).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8140","key":"2952_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0140-6736(79)91494-6","volume":"2","author":"AM McGregor","year":"1979","unstructured":"A.M. McGregor, B. Rees Smith, S. McLachlan, R. Hall, Effect of irradiation on thyroid- antibody production. Lancet 2(8140), 442\u2013444 (1979).","journal-title":"Lancet"},{"issue":"8","key":"2952_CR12","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1210\/jc.2004-2275","volume":"90","author":"M Lantz","year":"2005","unstructured":"M. Lantz, T. Vondrichova, H. Parikh, C. Frenander, M. Ridderstr\u00e5le, P. \u00c5sman P, M. \u00c5berg, L. Groop, B. Hallengren, Overexpression of immediate early genes in active Graves\u00b4 ophthalmopathy. J. Clin. Endocrinol. Metab. 90(8), 4784\u20134791 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"2952_CR13","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1089\/thy.2013.0654","volume":"24","author":"T Planck","year":"2014","unstructured":"T. Planck, B. Shahida, M. Sj\u00f6gren, L. Groop, B. Hallengren, M. Lantz, Association of polymorphisms in CTLA4, BTG2, CYR61, ZFP36 and SCD with Graves\u00b4 disease and ophthalmopathy. Thyroid 24(7), 1156\u20131161 (2014).","journal-title":"Thyroid"},{"issue":"10","key":"2952_CR14","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1089\/thy.2014.0153","volume":"24","author":"T Planck","year":"2014","unstructured":"T. Planck, B. Shahida, H. Parikh, K. Str\u00f6m, P. \u00c5sman, H. Brorson, B. Hallengren, M. Lantz, Immediate early genes are overexpressed in smokers with Graves\u00b4ophthalmopathy compared to non-smokers. Thyroid 24(10), 1524\u20131532 (2014).","journal-title":"Thyroid"},{"issue":"2","key":"2952_CR15","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1159\/000495504","volume":"8","author":"O Lindgren","year":"2019","unstructured":"O. Lindgren, P. Asp, A. Sundl\u00f6v, J. Tennvall, B. Shahida, T. Planck, P. \u00c5sman, M. Lantz, The effect of radioiodine treatment on TRAb, anti-TPO and anti-TG in Graves\u00b4 disease. Eur. Thyroid J. 8(2), 64\u201369 (2019).","journal-title":"Eur. Thyroid J."},{"issue":"1","key":"2952_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2249.2004.02424.x","volume":"136","author":"MJ Simmonds","year":"2004","unstructured":"M.J. Simmonds, S.C.L. Gough, Unravelling the genetic complexity of autoimmune thyroid disease: HLA, CTLA-4 and beyond. Clin. Exp. Immunol. 136(1), 1\u201310 (2004).","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"2952_CR17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1056\/NEJM199801083380201","volume":"338","author":"L Bartalena","year":"1998","unstructured":"L. Bartalena, C. Marcocci, F. Bogazzi, L. Manetti L, M.L. Tanda, E. Dell Unto E, G. Bruno-Bossio, M. Nardi, M.P. Bartolomei, A. Lepri, G. Rosso, E. Martino, A. Pincera, Relation between therapy for hyperthyroidism and the course of Graves\u00b4ophthalmopathy. N. Engl. J. Med. 338(2), 73\u201378 (1998).","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"2952_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM199206253262603","volume":"326","author":"L Tallstedt","year":"1992","unstructured":"L. Tallstedt, G. Lundell, O. Torring, G. Wallin, J.G. Ljunggren, H. Blomgren, A. Taube, Occurrence of opthalmopathy after treatment for Graves\u00b4hyperthyroidism. The thyroid study group. N. Engl. J. Med. 326(26), 1773\u20131788 (1992).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2952_CR19","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3899\/jrheum.180262","volume":"46","author":"MA Gianfrancesco","year":"2019","unstructured":"M.A. Gianfrancesco, L. Trupin, S. Shiboski, M. Van der Laan, J. Graf, J. Imboden, J. Yazdany, G. Schmajuk, Smoking is associated with disease activity in rheumatoid arthritis: a longitudinal study controlling for time-varying covariates. J. Rheumatol. 46(4), 370\u2013375 (2019).","journal-title":"J. Rheumatol."},{"issue":"66","key":"2952_CR20","doi-asserted-by":"publisher","first-page":"110614","DOI":"10.18632\/oncotarget.22702","volume":"8","author":"Y Tu","year":"2017","unstructured":"Y. Tu, G. Fan, Y. Dai Y, T. Zeng, F. Xiao, L. Chen, W. Kong, Association between rs3087243 and rs231775 polymorphism within the cytotoxic T-lymphocyte antigen 4 gene and Graves\u2019 disease: a case\/control study combined with meta-analyses. Oncotarget 8(66), 110614\u2013110624 (2017).","journal-title":"Oncotarget"},{"issue":"8","key":"2952_CR21","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/sj.gene.6364018","volume":"4","author":"Y Ban","year":"2003","unstructured":"Y. Ban, T.F. Davies, D.A. Greenberg, A. Kissin, B. Marder, B. Murphy et al. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immunity 4(8), 586\u2013593 (2003).","journal-title":"Genes Immunity"},{"issue":"11","key":"2952_CR22","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.4049\/jimmunol.165.11.6606","volume":"165","author":"T Koukki","year":"2000","unstructured":"T. Koukki, Y. Sawai, C.A. Gardine, M. Fisfalen, M. Alegre, L.J. De Groot, CTLA-4 gene polymorphism at position 49 in exon 1 reduces the inhibitory function of CTLA-4 and contributes to the pathogenesis of Graves\u00b4 disease. J. Immunol. 165(11), 6606\u20136611 (2000).","journal-title":"J. Immunol."},{"issue":"2","key":"2952_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clim.2007.01.003","volume":"123","author":"D Saverino","year":"2007","unstructured":"D. Saverino, R. Brizzolara, R. Simone, A. Chiappori, F. Militenda-Floriani, G. Pesce, M. Bagnasco, Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin. Immunol. 123(2), 190\u2013198 (2007).","journal-title":"Clin. Immunol."},{"issue":"5","key":"2952_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1530\/EJE-09-0600","volume":"161","author":"J Daroszewski","year":"2009","unstructured":"J. Daroszewski, E. Pawlak, I. Karabon, I. Frydecka, A. Jonkisz, M. Slowik, M. Bolanowski, Soluble CTLA-4 receptor an immunological marker of Graves\u00b4 disease and severity of ophthalmopathy is associated with CTLA-4 Jo31 and CT60 gene polymorphisms. Eur. J. Endocrinol. 161(5), 787\u2013793 (2009).","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"2952_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s13317-010-0011-7","volume":"1","author":"D Saverino","year":"2010","unstructured":"D. Saverino, R. Simone, M. Bagnasco, G. Pesce, The soluble CTLA-4 receptor and its role in autoimmune diseases: an update. Auto Immun Highlight 1(2), 73\u201381 (2010).","journal-title":"Auto Immun Highlight"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02952-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02952-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02952-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T09:13:18Z","timestamp":1646125998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02952-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["2952"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02952-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-883457\/v1","asserted-by":"object"}]},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The regional research ethics committee approved the study in Lund, Sweden (project number 160610). Informed consent was obtained from participating patients after a full explanation of the purpose and nature of all procedures used.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The patients provided written informed consent for disclosing clinical and imaging data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}